Jane Street Group LLC Lowers Position in Nkarta, Inc. (NASDAQ:NKTX)

Jane Street Group LLC lessened its stake in Nkarta, Inc. (NASDAQ:NKTX) by 63.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 56,919 shares of the company’s stock after selling 99,858 shares during the quarter. Jane Street Group LLC owned approximately 0.08% of Nkarta worth $257,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Wellington Management Group LLP increased its position in Nkarta by 24.8% during the third quarter. Wellington Management Group LLP now owns 216,341 shares of the company’s stock valued at $978,000 after acquiring an additional 43,035 shares during the last quarter. State Street Corp increased its position in Nkarta by 1.4% during the third quarter. State Street Corp now owns 1,098,062 shares of the company’s stock valued at $4,963,000 after acquiring an additional 15,569 shares during the last quarter. Erste Asset Management GmbH bought a new position in Nkarta during the third quarter valued at $33,000. Wasatch Advisors LP increased its position in Nkarta by 31.7% during the third quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company’s stock valued at $8,293,000 after acquiring an additional 442,125 shares during the last quarter. Finally, FMR LLC increased its position in Nkarta by 97.1% during the third quarter. FMR LLC now owns 133,149 shares of the company’s stock valued at $602,000 after acquiring an additional 65,600 shares during the last quarter. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on NKTX shares. Rodman & Renshaw started coverage on shares of Nkarta in a research report on Wednesday, October 9th. They set a “buy” rating and a $14.00 price objective on the stock. Needham & Company LLC cut their price target on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Mizuho cut their price target on shares of Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a report on Thursday, November 21st. RODMAN&RENSHAW upgraded shares of Nkarta to a “strong-buy” rating in a report on Wednesday, October 9th. Finally, HC Wainwright cut their price target on shares of Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, November 11th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $15.00.

Nkarta Stock Performance

NKTX stock opened at $2.35 on Friday. The firm has a market cap of $165.84 million, a price-to-earnings ratio of -1.25 and a beta of 0.85. The firm has a 50-day simple moving average of $2.61 and a two-hundred day simple moving average of $4.30. Nkarta, Inc. has a one year low of $2.08 and a one year high of $16.24.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.